Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 5/20 | 0.74 |
| ▸ | PRKD3 | O94806 | 4/20 | 0.74 |
| ▸ | PRKCG | P05129 | 4/20 | 0.74 |
| ▸ | PRKCB | P05771 | 4/20 | 0.74 |
| ▸ | PRKCH | P24723 | 4/20 | 0.74 |
| ▸ | PRKCI | P41743 | 4/20 | 0.74 |
| ▸ | PRKCE | Q02156 | 4/20 | 0.74 |
| ▸ | PRKCQ | Q04759 | 4/20 | 0.74 |
| ▸ | PRKCZ | Q05513 | 4/20 | 0.74 |
| ▸ | PRKCD | Q05655 | 4/20 | 0.74 |
| ▸ | PRKD1 | Q15139 | 4/20 | 0.74 |
| ▸ | USP2 | O75604 | 2/20 | 0.74 |
| ▸ | TP53 | P04637 | 2/20 | 0.74 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.74 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.74 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.74 |
| ▸ | TSHR | P16473 | 1/20 | 0.74 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12925019 | 1.00 | PRKCA (0.74) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL12950479 | 1.00 | PRKCA (0.74) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL19344745 | 0.93 | PRKCA (0.79) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL12925018 | 0.93 | PRKCA (0.67) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL29762786 | 0.93 | PRKCA (0.79) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL1537765 | 0.93 | PRKCA (0.79) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL18399929 | 0.91 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL21981002 | 0.91 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL362736 | 0.91 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH | |
| SCHEMBL18628313 | 0.91 | PRKCA (0.71) | PRKCAPRKD3PRKCGPRKCBPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10722484-B2 | Methods of cancer treatment | K-GEN, INC. (US) | 2020-07-28 | — | — | US | disclosed |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | Ferro Therapeutics, Inc. | 2020-05-07 | — | — | US | disclosed |
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | K-GEN THERAPEUTICS, INC. | 2019-10-03 | — | — | US | disclosed |
| WO-2017156350-A1 | METHODS OF CANCER TREATMENT | K-GEN, INC. (US) | 2017-09-14 | — | — | WO | disclosed |
| US-8816122-B2 | Prostratin analogs, bryostatin analogs, prodrugs, synthetic methods, and methods of use | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2014-08-26 | — | — | US | disclosed |
| US-20110014699-A1 | PROSTRATIN ANALOGS, BRYOSTATIN ANALOGS, PRODRUGS, SYNTHETIC METHODS, AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110014699-A1 | PROSTRATIN ANALOGS, BRYOSTATIN ANALOGS, PRODRUGS, SYNTHETIC METHODS, AND METHODS OF USE | PLAT, PTGIR, PTGFR | PRKCA 1100/4885PRKD3 571/4885PRKCG 771/4885 |
| US-20200138829-A1 | METHODS OF CANCER TREATMENT | AIFM2, GPX4, DDIT3 | PRKCA 953/4885PRKD3 1478/4885PRKCG 1498/4885 |
| US-20190298679-A1 | METHODS OF CANCER TREATMENT | PRKCI, PRKCH, PRKCZ | PRKCA 4/4885PRKD3 43/4885PRKCG 6/4885 |
| US-10722484-B2 | Methods of cancer treatment | PRKCI, PRKCH, PRKCZ | PRKCA 4/4885PRKD3 43/4885PRKCG 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.